Gotham Asset Management LLC Purchases 107,009 Shares of Biogen Inc. $BIIB

Gotham Asset Management LLC grew its position in shares of Biogen Inc. (NASDAQ:BIIB) by 65.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 270,498 shares of the biotechnology company’s stock after buying an additional 107,009 shares during the quarter. Gotham Asset Management LLC’s holdings in Biogen were worth $37,891,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of BIIB. Empowered Funds LLC lifted its holdings in Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after acquiring an additional 2,777 shares during the period. Focus Partners Wealth increased its position in shares of Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after purchasing an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Biogen during the 2nd quarter worth $216,000. Allworth Financial LP boosted its holdings in shares of Biogen by 114.3% in the 2nd quarter. Allworth Financial LP now owns 2,179 shares of the biotechnology company’s stock worth $274,000 after buying an additional 1,162 shares during the last quarter. Finally, Vise Technologies Inc. bought a new position in Biogen during the second quarter valued at about $398,000. 87.93% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. UBS Group assumed coverage on shares of Biogen in a report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price objective for the company. Piper Sandler increased their target price on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Mizuho raised their price target on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Jefferies Financial Group lifted their price target on shares of Biogen from $190.00 to $210.00 and gave the stock a “buy” rating in a report on Friday, November 28th. Finally, Barclays started coverage on Biogen in a research note on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price objective on the stock. Twelve analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $205.04.

Biogen Stock Performance

NASDAQ BIIB opened at $181.55 on Monday. The company’s 50 day simple moving average is $184.10 and its two-hundred day simple moving average is $167.19. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41. The stock has a market capitalization of $26.64 billion, a PE ratio of 20.61, a P/E/G ratio of 1.44 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same period in the previous year, the business earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Transactions at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.